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Introduction
Caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), the COVID-19 outbreak has 
spread to more than 180 countries, with the USA 
reporting the most confirmed cases worldwide as of May, 
2020, and widespread infection (ie, reports of COVID-19 
in all 50 states). The case fatality rate (believed to be at 
least 1%) is uncertain and might vary by country.1 
Quarantine and physical distancing measures have been 
implemented in most jurisdictions to slow down the 
spread of the virus.
Older and immunocompromised populations appear to 
be at a higher risk for severe, potentially life-threatening 
illness related to COVID-19 compared with the general 
population, with reported case fatality rates as high as 15% 
in patients aged 80 years or older.2 This observation 
presents a particular concern for patients with myeloid 
neoplasms, including acute myeloid leukaemia, myelo-
dysplastic syndromes, myelo prolif erative neoplasms, and 
overlap disorders with features of both myelodysplastic 
syndromes and myelo proliferative neoplasms, all of which 
present at a median age of 65–70 years.3,4 Although patients 
with acute lymphocytic leukaemia are generally younger, 
the age distribution at presentation is bimodal, with an 
increasing incidence of disease in patients older than 
45 years. Moreover, treatment for acute lymphocytic 
leukaemia is highly immuno sup pressive and often 
prolonged in duration; thus, the risk of complications 
related to COVID-19 in these patients is a concern.
Early data from the Chinese National Database 
Repository suggest an over-representation of patients with 
cancer in the COVID-19 cohort.5 COVID-19-related case 
fatality rates are estimated to be 5·6% in those with 
cancer,2 and patients with cancer are at a 3·5 times higher 
risk of severe COVID-19 compared with the general 
population.5 Additionally, case fatality rates of up to 37% 
have been reported in patients with haematological 
malignancies and COVID-19.6 One study found that case 
fatality rates were much higher in hospitalised patients 
with haematological cancers who developed COVID-19 
than in hospitalised health-care providers with COVID-19.7 
However, the exact incidence of COVID-19 in patients 
with cancer in general, and in patients with leukaemias in 
particular, is unclear.
Resource allocation that prioritises the care of patients 
with COVID-19 will affect the care of patients with other 
serious medical conditions such as haematological 
malignancies. Compounding the problem is the dis-
ruption to the timely delivery of cancer-directed therapies 
because of constraints on access to healthcare and the 
supply of blood products, and the disruption to the 
supply chain of drug therapies and medical supplies 
during the pandemic. Moreover, the man power and time 
needed in screening for SARS-CoV-2 and the risks and 
consequences of SARS-CoV-2 infection among health-
care personnel have had an effect across all diagnostic 
specialities.8 Therefore, the minimisation and rationing 
of oncology care, while assuring the best possible 
treatment for patients with cancer, requires pandemic 
planning and collaboration by haematology and oncology 
representatives, local health organisations, and policy 
makers.9
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The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health 
crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general 
population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms 
amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, 
clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We 
recognise that these recommendations might be more applicable to high-income countries and might not be 
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and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the 
care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of 
recommendations from international experts.
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This Viewpoint provides a summary of the current 
challenges in caring for patients with acute leukaemias 
(ie, acute myeloid leukaemia and acute lymphocytic 
leukaemia) and other myeloid neoplasms (ie, myelodys-
plastic syndromes, myeloproliferative neoplasms, and 
overlap syndromes), and offers a consensus on clinical 
practice guidance for optimal care in both the university 
and community health-care settings. The paucity of 
evidence-based data to guide leukaemia management 
during the pandemic prompted an online discussion, 
which initially involved leukaemia experts from highly 
affected areas in the USA, in which aspects of leukaemia 
care during the initial days of the COVID-19 pandemic 
were discussed. Subsequently, sharing this collective 
experience with the larger community of leukaemia care 
providers was recognised to be prudent, given the wide 
and rapidly progressing effects of the pandemic. To gain 
further input and perspective from different parts of 
the USA and other countries around the world, additional 
authors were invited to participate in the collaborative 
effort on the basis of their speciality and location. The 
experts on our panel are haematologists and oncologists 
who are highly specialised in leukaemia, myeloid 
neoplasms, and transplant care. Discussions were held 
through virtual, online meetings. Given the scarcity of 
evidence-based data on the management of leukaemias in 
the context of COVID-19, recommendations in this 
Viewpoint are based largely on expert opinion and 
experience, and complement the guidelines issued by 
relevant medical societies.
Because of the fluid health-care situation amid a rapidly 
evolving outbreak, the actions and contingency plans 
proposed in this Viewpoint should be considered in the 
context of disruptions to the local health system. We 
address various aspects of clinical management and 
provide specific suggestions to optimise the treatment of 
patients with haematological malignancies during the 
COVID-19 pandemic (panel 1).10–13
Resource allocation
Patients with haematological malignancies undergoing 
therapy require expert supportive care services that can be 
severely strained during a pandemic. Despite preparedness 
plans prioritising the support and safety of the health-care 
staff, a considerable number of health-care personnel 
will probably become unavailable because of sickness, 
mandated quarantines, fear of exposure, or concerns about 
family safety.8,14 Furthermore, some personnel will be 
required to, or volunteer to, take on additional patient care 
responsibilities, could come to work regardless of a high 
personal risk (eg, from old age or comorbid conditions), 
adopt not yet fully proven mitigation strategies, or 
inadvertently expose other essential colleagues, which is a 
particular risk given the high incidence of subclinical 
infections.15
Challenges in resource allocation are likely to be greatest 
at institutions already functioning at their maximum 
workforce capacity.8 Physical distancing measures and 
efforts to minimise the exposure of patients with 
comorbidities, such as haematological malignancies, to 
health-care environments will have detrimental down-
stream effects on the delivery of healthcare, including 
fewer in-person patient visits, delays in timely laboratory 
testing, interruptions to chemotherapy administration 
(despite many treatments depending on timely, cyclic 
administration), and delays to surgical and radiation 
therapy planning.16 Patients with haematological malig-
nancies should follow standard precautions related to 
COVID-19 and minimise physical contact, similar to the 
recommendations for older patients.
Specific to patients with haematological malignancies, 
physical distancing measures and fear of infection have 
an effect on the willingness and ability of volunteers to 
donate blood products, resulting in potential shortages of 
red blood cells, platelets, and plasma factors. Consequently, 
institutions could implement more restrictive transfusion 
guidelines, liberalise the use of erythroid growth factors, 
or do both, to decrease transfusion needs. Delaying the 
administration of therapies, including cellular and 
immunological approaches, for which supportive inter-
ventions (eg, tocilizumab) might be commandeered to 
manage SARS-CoV-2 infections, needs to be considered.
Strategies to reduce nosocomial SARS-CoV-2 
transmission
To maximise the effect of physical distancing measures, 
in-person hospital visits should be minimised as much as 
possible for the safety of both the patients and the staff.17 
It is also recommended that all personnel involved in 
the care of patients with haematological malignancies 
(including patients asymptomatic for COVID-19), in 
addition to using appropriate personal protective equip-
ment and infection control procedures, be routinely tested 
for SARS-CoV-2 if logistically possible, and the frequency 
of which should be based on the local patterns and 
frequency of SARS-CoV-2 infections.16,17 Additionally, we 
strongly recommend that COVID-19 areas and oncology 
departments in hospitals are strictly separated, with a view 
towards keeping the cancer wards and clinics free of 
COVID-19. One approach, in such cases, might be to have 
separately staffed wards: one for patients who are positive 
for SARS-CoV-2, one for patients who are negative for 
SARS-CoV-2, and a third to isolate patients until their 
COVID-19 status is known. Each nursing unit should 
develop and follow pre-emptive strategies to avoid patient–
patient and staff–patient transmission, especially in wards 
with patients who are immunosuppressed and in whom 
the adverse consequences of such transmission might be 
serious. Limiting in-person visits for patients in an in-
house palliative care unit can have a considerable effect on 
both patients and families, with respect to quality of life.
The implementation of non-traditional strategies to 
deliver healthcare, such as telehealth platforms, has the 
potential to partially mitigate the negative effect physical 
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Panel 1: Summary of key recommendations
Shifting care to the outpatient setting
Leukaemia providers should determine how long patients can 
be managed for without in-person follow-up, blood tests, and 
therapies, including blood product support. The frequency of 
clinic visitations should be individualised and will vary by the 
acuity of the illness, the need for close monitoring of potential 
complications during therapy, and blood product and 
medication supply, among other factors.
Telehealth services (eg, telemedicine and video conferencing) 
provide valuable delivery platforms to facilitate adherence to 
physical distancing guidelines and should be preferred for 
patient–provider encounters that do not require infusional 
therapy, transfusions, or laboratory tests.
Ethics, resource allocation, and advance care planning
Haematologists caring for patients under crisis standards of 
care are advised to consult with the centralised hospital ethics 
committee to address complex ethical issues involving the 
rationing of lifesaving interventions when the situation arises.
Although the overarching goal is to offer potentially curative 
treatments when appropriate, the futility of further treatment 
in patients with advanced, multi-line refractory disease, who 
have exhausted standard-of-care options and are without 
access to clinical trials, must be considered.
Haematologists should have goals-of-care discussions with all 
patients with haematological malignancies under their care, 
particularly older patients (>60 years) and those with a 
haematological malignancy associated with a poor prognosis. 
Such goals-of-care discussions in the COVID-19 era, by stressing 
the potential resource limitations, might considerably reduce 
the proportion of patients with advanced disease who elect for 
intubation, thereby resulting in the modification of current 
treatment goals, preventing inappropriate escalation of care.10
Blood product and transfusion management
During times of blood product shortages, we recommend 
maintaining a haemoglobin serum concentration of more than 
7 g/dL for patients with haematological malignancies requiring 
red blood cell transfusion, with a higher threshold for those 
with burdensome symptoms or serious comorbidities such as 
active cardiopulmonary disease. Consider increasing the 
intervals between transfusion episodes, with more red blood 
cell units transfused per episode.
We recommend a phased response for platelet transfusions on 
the basis of the estimation of available blood bank resources. 
During times of severe shortage, avoiding prophylactic 
transfusions even if platelet concentration is less than 
10 000 platelets per µL (in the absence of bleeding), with 
consideration of the prophylactic use of antifibrinolytics, could 
be considered.
Growth factor support
The benefit of minimising the duration of neutropenia with 
growth factors must be balanced against the rare, but 
potential, risk of worsening the pulmonary complications 
related to COVID-19.11 There is a theoretical risk of worsening 
pulmonary inflammatory injury by the use of growth factors in 
moderate-to-severe, active COVID-19, one setting in which the 
use of growth factors should be reconsidered.12,13
Clinical trials
Continued participant accrual in clinical trials investigating 
drugs of probable therapeutic benefit and in late salvage trials 
offering the only viable option for patients with advanced 
leukaemia is recommended, whenever logistically possible.
Enrolment in clinical trials, in which patients are randomly 
assigned to commercially available standard-of-care therapies, 
might place patients at unnecessary risk to comply with study-
related procedures, and therefore continued enrolment in these 
trials, in the pandemic, should be re-evaluated.
For patients with relapsed or refractory haematological 
malignancies for whom clinical trials represent the only viable 
treatment option, the decision to participate in a trial will need 
to be pursued on a case-by-case basis.
Onsite monitoring is inconsistent with physical distancing 
goals, and protocol deviations are unavoidable; the US Food and 
Drug Administration, the European Medicines Agency, Health 
Canada, and other regulatory agencies have issued guidance on 
the safe conduct of trials during the pandemic.
General approach to treatment and legal ramifications
Careful clinical judgment must balance the risks and benefits of 
various treatment options and patient burden to allow for the 
best possible outcomes. The goal should still be to not 
compromise care for patients whose cancer is curable, despite 
the pandemic.
Substituting standard-of-care intensive chemotherapy with 
potentially suboptimal, less intensive treatment regimens to 
reduce inpatient bed and intensive care bed use requires a 
transparent discussion between the patient and the provider.
Discussions with patients regarding deviations in therapy from 
the standard of care to lessen the risk of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection, proceeding with 
therapy with the possibility of greater morbidity in the event of a 
SARS-CoV-2 infection, or deviations in planned therapy if cancer 
centre resources are compromised unexpectedly, should be 
endorsed at a unit level and documented in the patient notes to 
show the process for these decisions.
Research agenda
The American Society of Hematology has launched a global 
registry initiative intended to provide periodically updated 
summaries of observational data to physicians. We encourage 
physicians who treat patients with leukaemia to submit their 
data on patients with haematological malignancies and 
COVID-19 to this publicly accessible resource. 
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distancing has on the delivery of cancer care.18 However, 
for patients with haematological malignancies, remote 
healthcare is often insufficient, given their need 
for frequent phlebotomies, transfusion support, and 
scheduled treatments. Health-care providers will need to 
prioritise patients on the basis of the urgency and the 
goals of care. In some cases, treatment and assessment 
can be safely delayed, and in-person visits can be avoided 
via the use of telehealth or remote communication 
approaches. In other cases, such as for patients who 
require urgent, life-sustaining or potentially curative 
therapies, in-person visits are essential. If possible, 
patients should receive therapy in their local area to 
minimise travel to large academic centres.
Ethical considerations
Because of rising demand and scarce resources, hospital 
systems face ethical challenges in the rationing of health-
care resources.19 Rationing access to, and services for, 
intensive care units to those who are critically ill and near 
the end of life poses a challenge for, and disrupts the 
equipoise of, the health-care provider. Rationing these 
lifesaving, yet finite, resources is an ethically complex 
decision making process that requires balancing and 
rectifying ethically competing goals.9,19 Community-based 
guidelines have been put in place during crisis standards 
of care to deal with the issues of resource use that could 
arise if lifesaving measures are in short supply.20 
We strongly advise haematologists and intensive care 
physicians caring for patients under crisis standards of 
care to consult with centralised hospital ethics committees 
who can provide guidance in cases where complex ethical 
issues involving the rationing of lifesaving interventions 
might arise. Although various a priori approaches have 
been suggested to facilitate resource triage during a 
pandemic, fair resource allocation at the patient level 
should be based on judgment by experienced intensive 
care physicians using established evidence-based 
prognostic scores. Useful online resources and publi c-
ations exist that outline frameworks for identifying key 
ethical issues during a pandemic and guidelines on ways 
to navigate these issues.21,22 The availability of adequate 
and timely intensive care support is crucial for oncology 
and haematology treatment programmes (eg, intensive 
chemo therapy and allogeneic haematopoietic stem-cell 
trans plantation). In these circumstances, not only should 
any uncertainties regarding the availability of intensive 
care unit support be considered during treatment 
planning discussions, but the haematologist must be 
prepared to deliver precise information on life expectancy 
and potential long-term individual outcomes to the 
intensive care provider. The haematologist should be 
willing to appro priately advocate for the treatment of their 
patients with curable haematological malignancies in 
cases of overzealous restriction of resources. In essence, 
we must recognise that some patients with haematological 
malignancies who require admission to intensive care 
units for reasons related or unrelated to COVID-19 have 
cancers that are still curable, so deprioritising their access 
to intensive care units should be avoided.
Transfusion support
Blood product transfusion support is an integral aspect of 
supportive care, and many curative therapies (eg, intensive 
induction and allogeneic haematopoietic stem-cell trans-
plantation) require that patients reliably receive blood 
product transfusion support during protracted myelo-
suppression. Conversely, patients without the prospect of 
cure might still glean clinical benefit from non-intensive 
therapies or best supportive care, and transfusion support 
is often fundamental for these patients.23 Patients receiving 
chronic transfusion support not only represent a con-
siderable logistical challenge to the hospital system’s blood 
bank capability, but are also a potential source of 
SARS-CoV-2 transmission because of frequent exposure to 
other patients and staff.
Concerns over blood donor safety in the COVID-19 era, 
taken together with physical distancing and quarantining 
initiatives, have prompted donor deferral to the detriment 
of the pool of blood product donors. An inherently high 
demand for blood products among patients with 
haematological malignancies, coupled with a diminished 
donor pool and a reduction in blood bank service 
providers, places severe strain on the cancer centre’s 
capacity to provide transfusions.
Although most blood management groups generally 
follow restrictive thresholds for transfusion based on 
national guidelines (ie, transfusion is not indicated until 
the haemoglobin serum concentration is 7–8 g/dL),24 this 
approach might not be appropriate for certain populations 
at high risk of complications related to anaemia, including 
those who are older (>60 years) and those who have 
cardiovascular disease.25 Controversy remains about the 
appropriate haemoglobin trigger threshold for red blood 
cell transfusion in patients with various myeloid 
neoplasms,26 resulting in a wide variation in transfusion 
practices among physicians and institutions.27 Regardless, 
contingency plans for emergency transfusion might 
require the adoption of increasingly restrictive transfusion 
thresholds to match the constraints on blood product 
supply. Consideration should also be given to increasing 
the interval between transfusion episodes and increasing 
the number of transfusion units given per episode, thereby 
reducing the number of patient visits to health-care 
institutions.28 Where possible, community-based blood 
draws for blood count and cross-matching should be 
implemented. Nonetheless, a severe shortage of blood 
products and uncertainty about future supply should 
prompt clinicians to discuss risks and benefits with their 
patients, especially if intensive myelosuppressive chemo-
therapy is under consideration.
Given the short shelf life of platelets, platelet 
availability is particularly problematic in the event of 
blood product shortages.28 We propose a stepwise 
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approach to platelet transfusion in patients with 
haematological malignancies on the basis of the 
estimation of resources in the local blood bank. If 
platelet resources are unaffected locally, continue with 
local institutional policies. If platelet availability is 
reduced, initial strategies to conserve platelet stocks 
include avoiding prophylactic platelet transfusions for 
surgical interventions by deferring non-urgent proced-
ures and establishing an inpatient and outpatient 
threshold for prophylactic platelet transfusions of less 
than 10 000 platelets per µL for the overall population 
with chronic needs. For situations in which the available 
pool of platelet products is very low, we advocate for a 
strategy of non-prophylactic platelet transfusion on the 
basis of data showing no survival benefit for prophylactic 
platelet transfusions among patients with haematological 
malignancies undergoing chemotherapy.29,30 Additional 
strategies, in times of serious shortage, could include 
avoiding prophylactic platelet transfusions with rare 
exceptions (eg, disseminated intravascular coagulation 
and coagulopathy of acute promyelocytic leukaemia), 
and considering the use of prophylactic antifibrinolytics, 
such as aminocaproic acid or tranexamic acid, if the risk 
of bleeding is high in patients negative for SARS-CoV-2 
infection.31
Although early studies32,33 have presented conflicting 
data on the detection of SARS-CoV-2 RNA and infectious 
virus in blood specimens, and blood borne transmission 
of SARS-CoV-2 has yet to be reported, the US Food and 
Drug Administration (FDA) recommends donor deferral 
measures to prevent the transmission of SARS-CoV-2 via 
blood components.34 These measures include the careful 
screening of blood donors for symptoms of COVID-19 
and the recalling of untransfused blood products from 
infected donors. To address the urgent need for blood 
components in certain areas, the FDA has revised these 
recommendations by, for example, reducing the deferral 
period in populations at high risk, such as men who have 
sex with men and donors who have travelled to or from 
COVID-19 endemic areas, to encourage more blood 
donations.35
Growth factor support and prophylactic 
antimicrobials
The use of prophylactic antimicrobials constitutes an 
important aspect of leukaemia management for disease-
induced and chemotherapy-induced neutropenia.36 Many 
chemotherapy protocols for myeloid neoplasms do not 
incorporate the routine use of haematopoietic colony-
stimulating factors (eg, granulocyte colony-stimulating 
factor) to prevent chemotherapy-induced neutropenia. 
The use of growth factors, such as granulocyte colony-
stimulating factor or other myeloid growth factors, 
should probably be avoided in patients with moderate-to-
severe SARS-CoV-2 infection given the potential risk of 
exacerbating inflammatory pulmonary injury, especially 
in the case of patients with disorders that have overlap 
between myelodysplastic syndromes and myelo pro lif-
erative neoplasms.12,13
Although patients with haematological malignancies 
and neutropenia are potentially at a higher risk of 
having severe COVID-19 compared with the general 
population because of an immunocompromised state, 
the differ ential diag nosis for neutropenic fever remains 
broad, and empirical antibacterial therapy should be 
initiated promptly pending further workup. We recom-
mend screening for SARS-CoV-2 in all patients with 
haema tological malignancies and a fever whenever 
possible, and before haematopoietic stem-cell trans-
plantation, cellular therapy (such as with chimeric 
antigen receptor T cells), and chemotherapy. We recom-
mend that when SARS-CoV-2 is identified in a patient 
with neutropenic fever (with or without respiratory 
symptoms), well established protocols of broad-
spectrum (and even antifungal) agent admini stration 
should be applied, along with COVID-19 therapies 
specific to the institution.
Given the safety concerns surrounding hepatotoxicity 
and QT interval prolongation (corrected for heart rate) 
with some of the agents used to treat patients with 
COVID-19, such as hydroxychloroquine and azithro-
mycin, we do not recommend prophylaxis with these 
agents for patients with haematological malignancies 
negative for SARS-CoV-2. However, several ongoing 
clinical trials in North America and elsewhere should 
provide further guidance on this point (eg, NCT04330495 
and NCT04329923).
Because of the increasing concern that microthrombosis 
is contributing to the pathophysiology of COVID-19, 
many institutions are now adopting prophylactic or 
therapeutic anticoagulation as a part of their treatment 
algorithms for the infection.37 Careful consideration and 
frequent monitoring of coagulation markers and platelet 
counts, in the context of acute leukaemia, should be 
undertaken when making decisions regarding the 
administration of anticoagulation.
Clinical trial participation
Minimising the disruption to clinical care and preserving 
the integrity of clinical trials is a major challenge during a 
pandemic. Physical distancing and other mitigation 
efforts in the community negatively affect several 
standard clinical trial procedures, including patient 
accrual, the optimal delivery of interventions, patients’ 
adherence to medical treatments, patient monitoring and 
adverse event reporting, and the evaluation of outcome 
measures.38,39 In addition, most laboratories that do 
correlative studies, such as biomarker assessments, 
pharmacokinetic assays, and pharmacodynamic assays, 
are closed. The effect of these important mitigation 
measures on preclinical research should also be 
recognised because leukaemia translational laboratories 
are suspending or drastically scaling back operations to 
comply with physical distancing requirements.40
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To ease the burden on participating health-care facilities 
now prioritising COVID-19 studies, academic centres and 
drug sponsors have begun to suspend patient enrolment 
in many ongoing interventional trials. Some centres have 
needed to put accrual to phase 3 trials and some phase 2 
trials on hold when a viable standard-of-care option exists. 
However, we must maintain and support continuing 
clinical intervention trials whenever possible, including 
the continued accrual of new partici pants, while ensuring 
patient safety and study feasibility.39 This support should 
apply to randomised trials investi gating the effects of 
interventions of proven clinical benefit and trials involving 
multi-line refractory patients who have exhausted all 
alternative standard-of-care options.
Recognising the challenges affecting standard protocol 
procedures, the FDA and Health Canada have issued 
guidance for doing clinical trials during the COVID-19 
pandemic, particularly emphasising patient safety.41,42 In 
Europe, a COVID-19 pandemic task force set up by the 
European Medicines Agency in collaboration with 
the  Clinical Trials Facilitation and Coordination Group 
has been established to take quick and coordinated 
regulatory action related to COVID-19 medicines.43
In accordance with good clinical practice, drug sponsors, 
protocol investigators, local institutional review boards, 
and ethics committees should continue to establish 
memoranda of policies that explain how clinical trial 
activities can be done effectively while allowing for 
possible disruptions in usual care at the study sites.42 
Disruptions related to the pandemic, including when 
patients become symptomatic from a SARS-CoV-2 
infection during therapy, might necessitate protocol 
Panel 2: Summary of treatment guidelines for the management of adult acute myeloid leukaemia
General recommendations
• Consider delaying treatment unless there is an urgent need 
to initiate treatment 44
• Screen all patients in need of intensive induction treatment 
for severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) before treatment initiation:
• If the test is positive, consider delaying treatment by 
10–14 days, with careful consideration of cytoreductive 
agents in the interim; consult with infectious disease 
specialists regarding the criteria to clear the patient for 
chemotherapy (ie, two negative COVID-19 tests and an 
absence of symptoms)
• If the test is negative, repeat the test after 24 h if there is 
high clinical suspicion because the RT-PCR test has a 
sensitivity of about 70%45
• If the patient is positive for SARS-CoV-2 and there is an 
urgent need to initiate induction treatment, consider 
treatment with close monitoring for any evolving and 
related COVID-19 symptoms
• Consider treatment discontinuation if the patient develops 
symptoms of COVID-19; early initiation of cytokine 
modulators could be considered for patients with COVID-19 
who are symptomatic from COVID-1946,47
• Prioritise outpatient management following induction 
therapy once the necessary follow-up is ensured48
Induction
• For younger (18–65 years) or fit patients (who are deemed 
eligible for intensive chemotherapy on the basis of general 
health and performance status) who are newly diagnosed:
• Treatment induction with cytarabine and an 
anthracycline (eg, 7 days of cytarabine infusion and 
3 days of an anthracycline infusion, or similar) in 
non-acute promyelocytic leukaemia, with a specific 
regimen based on risk stratification, and all-trans 
retinoic acid with arsenic trioxide in non-high-risk acute 
promyelocytic leukaemia, should remain standard49
• Use caution with prophylactic corticosteroids to prevent 
differentiation syndrome during therapy for acute 
promyelocytic leukaemia
• If there are severe shortages in hospital bed capacity, 
support staff, or both, alternative low intensity, 
outpatient induction regimens (eg, a hypomethylating 
agent and venetoclax) might be necessary49,50
• For older patients (>65 years) deemed eligible for intensive 
chemotherapy:
• Outpatient treatment with a hypomethylating agent 
with or without venetoclax or targeted inhibitors should 
be strongly considered49,50
Consolidation
• Consider deferring patients without adverse risk disease 
who need allogeneic haematopoietic stem-cell transplants 
when they test negative for minimal residual disease
• Consider reducing the number of chemotherapy 
consolidation cycles with high-dose cytarabine and the 
cumulative cytarabine dose within each cycle49,51
• Consider maintenance therapy with a hypomethylating agent 
as an alternative to intensive post-remission therapy after 
careful consideration of the risks versus the benefits52
• Consider high-dose cytarabine consolidation as an alternative 
to autologous haematopoietic stem-cell transplantation
Supportive care
• The benefit of minimising the duration of neutropenia with 
growth factors must be balanced against the rare, 
but potential, risk of worsening the pulmonary complications 
related to COVID-19;49 the use of growth factors in patients 
with moderate-to-severe COVID-19 should be reconsidered
• Follow transfusion contingency plans
• Monitor patients for drug–drug interactions between 
venetoclax, ivosidenib, gilteritinib, and azole antifungals 
and COVID-19 therapies (eg, hydroxychloroquine and 
azithromycin)
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deviations. Suspension of all non-essential procedures 
related to the trial that do not directly ensure safety should 
be considered. For example, extended hospital visits for 
pharmacokinetic and pharmacodynamic studies and non-
crucial response assessments should be eliminated during 
the height of the COVID-19 pandemic, when the risk of 
exposure in the cancer centre outweighs any immediate 
direct benefit to the patient. Continuing patient access to 
the study drug, when approved by both the sponsor and 
the institutional review board, might include shipping the 
study drug directly to patients, mobile laboratory blood 
draws, and the approval of telehealth study visits.
Treating adult patients with acute leukaemias 
and myeloid neoplasms during the COVID-19 
pandemic
In the absence of evidence-driven clinical guidelines in the 
COVID-19 setting, the health-care provider must carefully 
balance the risks and the benefits when making a 
treatment recommendation. The administration of 
intensive chemotherapy amid an active pandemic can 
place patients at a high risk of contracting a severe 
SARS-CoV-2 infection, with potentially fatal conseq uences, 
and might lead to the need for intensive care. Considering 
the challenges faced by the oncology community in 
Panel 3: Summary of treatment guidelines for the management of adult acute lymphocytic leukaemia 
General recommendations 
• Consider delaying treatment if possible, given the risks of 
developing severe COVID-19 with chemotherapy53
• Test all patients for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) before treatment initiation:
• If the test is positive, consider delaying treatment by 
10–14 days, except intrathecal therapies for CNS 
symptoms 
• If the test is negative, repeat the test after 24 h if there is 
high clinical suspicion because the RT-PCR test has a 
sensitivity of about 70%45
• If the patient is positive for SARS-CoV-2 and initiation of 
induction treatment is urgently needed, consider 
treatment with close monitoring for any evolving and 
related COVID-19 symptoms; institute appropriate 
precautions (eg, use personal protective equipment) and 
obtain goals of care before initiating therapy
• Consider treatment discontinuation if the patient develops 
symptoms of COVID-19; early initiation of cytokine 
modulators could be considered for patients with COVID-19 
who are symptomatic from COVID-1946,47
Induction 
• In older patients (>65 years), consider minimising steroid 
exposure because of the concern that steroids could increase 
the risk of severe COVID-1954,55 
• In older patients (>65 years), consider reducing the dose of 
daunorubicin and PEGylated asparaginase during treatment 
induction 
• Delay treatment with anti-CD20 monoclonal antibodies if 
possible because these agents reduce immunoglobulin 
concentrations 
• Consider second-generation tyrosine kinase inhibitors with 
reduced dose steroids in Philadelphia chromosome-positive 
disease56
Consolidation 
• Consider blinatumomab if patients are positive for minimal 
residual disease after two cycles of chemotherapy
• Consider advancement to maintenance if patients are 
negative for minimal residual disease and have already 
received most of their treatment
Maintenance 
• In older patients (>65 years), consider reducing the dose of 
steroids and avoiding vincristine57
• Pending further evidence, prompt initiation of 
blinatumomab to treat minimal residual disease in 
Philadelphia chromosome-negative B-cell acute 
lymphocytic leukaemia remains standard58
Relapsed or refractory disease and transplantation
• Consider inotuzumab over blinatumomab as the first 
salvage option to reduce the duration of hospital stay57
• Consider delaying allogeneic haematopoietic stem-cell 
transplantation for patients in first complete remission
• Patients with relapsed or refractory acute lymphocytic 
leukaemia in second complete remission should have an 
allogeneic haematopoietic stem-cell transplant promptly, 
considering the high-risk nature of disease and the high risk 
of relapse57 
• If feasible, consider delaying therapy with T cells with 
chimeric antigen receptors directed to B-lymphocyte 
antigen CD19 for patients with relapsed or refractory acute 
lymphocytic leukaemia younger than 25 years for whom 
this therapy is approved by the US Food and Drug 
Administration 
Supportive care
• Consider liberal use of growth factor support in patients 
without COVID-19 to facilitate the recovery of neutrophil 
count11 and to maintain an absolute neutrophil count of 
more than 1000 cells per µL across all phases of therapy; 
the use of growth factors in moderate-to-severe COVID-19 
should be reconsidered given the potential risk of 
worsening the pulmonary complications related to 
COVID-19  
• Follow transfusion contingency plans 
• Monitor for drug–drug interactions between the drugs used 
to treat acute lymphocytic leukaemia and any potential 
therapies for COVID-19
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treating adult patients with myeloid neoplasms, major 
medical societies, including the American Society of 
Hematology, have released resources to help providers to 
care for patients with haematological malignancies 
(appendix pp 13–14). These intervention strategies are 
mainly aimed at mitigating the risk of inducing an 
immunocompromised state that can predispose patients 
to a potentially fatal SARS-CoV-2 infection, and reducing 
the effect of the pandemic on hospital bed capacity and 
intensive care capacity by decreasing the intensity and the 
length of chemotherapy exposure.
We have outlined a proposed general approach to the 
treatment of adult patients with acute myeloid leukaemia 
and acute lymphocytic leukaemia during the pandemic 
(appendix pp 15–16). We would like to emphasise that the 
situation remains fluid and individual clinical practice 
needs to be adapted to the local circumstances (eg, resource 
availability and local disease epidemiology) and to 
the individual patient. We have summarised the key 
considerations of the management approaches for patients 
with acute myeloid leukaemia (panel 2), acute lymphocytic 
leukaemia (panel 3), myeloproliferative neoplasms 
(panel 4), and myelodysplastic syndromes and overlap 
syndromes (panel 5) in the setting of the COVID-19 
pandemic. Many of our recommendations align with those 
of the COVID-19 advisory panels of the American Society 
of Hematology. We have outlined a detailed discussion on 
the rationales and available evidence supporting these 
recommendations in the appendix (pp 3–12). The 
underlying principles behind these recommendations are 
the need to minimise the risk of contracting SARS-CoV-2 
and reduce the severity of ensuing COVID-19 for patients 
by avoiding health-care exposure and periods of immuno-
suppression and providing effective disease-directed 
treatment. We acknowledge that these recom mendations 
reflect a compromise and partly deviate from routine 
practice in the non-COVID-19 setting. As the evidence 
base evolves, these recommendations should be critically 
re-evaluated and additional adjustments will probably 
become necessary in the future.
Many of the mitigation strategies and risk assessments 
we have outlined will be similar to those for lymphoid 
malignancies and plasma cell neoplasms. Consideration 
must be given to dose-attenuated regimens and careful 
growth factor use in the older population (>65 years) to 
reduce the risk of myelosuppression and the duration of 
hospitalisation. Suitable alternative regimens suggested 
by the National Comprehensive Cancer Network that can 
be managed on an outpatient basis might be preferred.64 
Specific additional considerations for patients with 
COVID-19, including the use of immunomodulatory 
therapeutic strategies to overcome T-cell immune dys-
function induced by therapies for multiple myeloma and 
lymphomas,65–69 should be addressed. A detailed discussion 
regarding changes to management approaches in aggres-
sive and indolent lymphomas, chronic lym pho cytic leuk-
aemia, multiple myeloma, and allogeneic haema topoietic 
stem-cell transplantation is beyond the scope of this 
Viewpoint and we refer the reader to other resources in 
which these topics are reviewed in more detail.70
Call for research on the effect of COVID-19 on 
patients with haematological malignancies
Many clinical trials are underway to investigate the 
efficacy of vaccines and various antiviral therapies 
targeting SARS-CoV-2, but the inclusion of patients with 
haematological malignancies in these trials is variable. 
Early and emerging data suggest that convalescent serum 
samples might be beneficial either for the prophylaxis of 
infection or the treatment of COVID-19, and it is hoped 
that patients with haematological malignancies will also 
be eligible for this intervention.71,72  Trials evaluating 
agents intended to dampen harmful inflammatory 
responses to SARS-CoV-2, such as JAK inhibitors 
(eg, NCT04320277), anti-IL-6 monoclonal antibodies (eg, 
NCT04322773), BET inhibitors (eg, NCT03936465), and 
Panel 4: Summary of treatment guidelines for the management of adult 
myeloproliferative neoplasms
Chronic myeloid leukaemia
• We do not recommend any changes in management with tyrosine kinase inhibitors at 
this point
• Patients with newly diagnosed disease should be started on tyrosine kinase inhibitor 
treatment as usual, extending visits and mobile laboratory blood draws where 
available; ensure patients have routine lab monitoring for cytopenias induced by 
treatment with a tyrosine kinase inhibitor and a 1–3 month supply of tyrosine kinase 
inhibitor to minimise pharmacy visits
• We do not recommend doing trials of tyrosine kinase inhibitor discontinuation during 
the COVID-19 pandemic
• In accelerated phase or blast phase disease, consider non-aggressive regimens with 
tyrosine kinase inhibitors
Philadelphia chromosome-negative myeloproliferative neoplasms
• Patients with essential thrombocythaemia or polycythaemia vera should continue 
current cytoreductive treatment with hydroxycarbamide, anagrelide, interferon alfa, 
or ruxolitinib
• Ensure that patients have a 3-month supply of agents to minimise pharmacy visits
• Whenever possible, avoid stopping ruxolitinib, especially in the setting of the 
COVID-19 pandemic, because ruxolitinib helps to prevent possible immune cytokine 
release syndrome
• Consider deferring the initiation of JAK inhibitors because of these agents’ 
immunosuppressive effects59
• Continue aspirin for thromboprophylaxis in patients with high-risk essential 
thrombocythaemia or polycythaemia vera; consider switching patients from oral 
anticoagulation to low-molecular-weight heparin in the setting of acute COVID-19
• Use erythropoiesis-stimulating agents and danazol to reduce the need for red blood 
cell transfusion on a case-by-case basis
• Delaying allogeneic haematopoietic stem-cell transplantation might be required 
given the current restrictions on resource allocation
• Consider a hypomethylating agent with or without ruxolitinib or venetoclax in blast 
phase disease, in the outpatient setting whenever possible, with a goal of doing 
allogeneic haematopoietic stem-cell transplantation when appropriate60
See Online for appendix
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BTK inhibitors (eg, NCT04346199), are prospectively 
evaluating treatment responses in patients with 
COVID-19 and a diagnosis of cancer. With the emergency 
use authorisation of remdesivir, made on the basis of 
early efficacy data, haematological effects, especially 
among patients receiving chemotherapy, should be 
considered.73 Until effective antiviral strategies are 
supported by data and made available, physical distancing, 
minimising hospital and office visits, telemedicine, and 
careful tailoring of individual treatment plans are 
essential strategies to mitigate the potential complications 
from COVID-19 in patients with haematological malig-
nancies. These measures can be especially challenging 
for older patients (>65 years) who might need increased 
assistance with daily care, transportation to clinic visits, 
or technological support.
With the COVID-19 outbreak likely to last months, and 
possibly recur in the future in a cyclical pattern,74 
epidemiological and outcome data defining populations at 
high risk of contracting severe COVID-19 will inform the 
development of a framework that incorporates pre-emptive 
strategies, such as the use of vaccines and antiviral drugs, 
to optimise outcomes for patients with haematological 
malignancies. Identifying patients who might have 
immunity to SARS-CoV-2, perhaps from previous expos-
ure, is similarly important, and reliable serological testing 
is therefore eagerly anticipated. These important research 
agendas will warrant investigation under controlled 
clinical trial settings that will explore not only their 
immediate benefits, but also other crucial aspects of 
administration, such as drug interactions between antiviral 
therapies and leukaemia treatments. Delineation of the 
effects of SARS-CoV-2 on haematopoiesis will have broader 
impli cations on haematopoietic stem-cell mobilisation and 
the use of growth factor support.75 Research on the effect of 
the COVID-19 outbreak on leukaemia outcomes, includ-
ing the role of delays in treatment, the selection of 
potentially suboptimal chemotherapy regimens, and 
complications directly related to COVID-19, will become 
feasible with the growing pool of infected patients and 
ongoing efforts to centralise these data.
Conclusions
The COVID-19 pandemic has severely strained the 
oncology community and the delivery of optimal care for 
patients with leukaemia and associated myeloid neo-
plasms. With local policy makers implementing various 
contingency measures to minimise the potential effect of 
this pandemic, the rationing of oncology care services has 
become a reality. The need to treat patients with potentially 
lifesaving, intensive chemotherapy presents an enormous 
challenge; the population’s associated immuno com-
promised state places an already susceptible population at 
even greater risk for contracting severe COVID-19. Setting 
early goals of care and discussing code status for all 
patients with haematological malignancies is imperative. 
Ethical issues surrounding the allocation of lifesaving 
interventions to critically ill patients, and the deter-
mination of treatment futility among patients without 
viable treatment options outside of a clinical trial, will 
need to be continually addressed.
Panel 5: Summary of treatment guidelines for the management of adult 
myelodysplastic syndromes and adult syndromes with overlap between 
myelodysplastic disease and myeloproliferative neoplasms
General recommendations
• Treatment decisions should be based on category in the revised international 
prognostic scoring system
• Established and newly diagnosed patients being considered for potentially 
myeloablative therapy should undergo testing for COVID-19 before treatment 
initiation with the same considerations as for patients with acute myeloid leukaemia
• The goals-of-care discussion and the importance of physical distancing should be 
emphasised because a large proportion of the patient population are older individuals  
(>65 years) with comorbidities who are at a high risk of mortality if diagnosed with 
COVID-19
High-risk myelodysplastic syndromes
• Close observation without definitive treatment is a reasonable strategy in patients 
with only modest cytopenias61
• Start newly diagnosed patients requiring treatment on a hypomethylating agent and 
continue treatment in patients already receiving these agents62
• Consider lengthening the duration between treatment cycles and reducing dosing 
within each cycle for patients that have had a response; maintain normal intervals 
until patients respond
• Avoid a delay of more than 6 weeks between cycles of hypomethylating agents
• Subcutaneous azacitidine is preferred over intravenous azacitidine to decrease the 
time spent at infusion centres and in contact with COVID-19 exposures
Lower risk myelodysplastic syndromes
• We recommend a watch-and-wait approach for most patients
• Erythropoiesis-stimulating agents (for patients naive to these agents) and 
luspatercept63 should be considered to minimise the need for red blood cell transfusions
• Consider deferring the initiation of lenalidomide in newly diagnosed patients with 
del(5q) disease given the risk for myelosuppression
Overlap syndromes
• We recommend a watch-and-wait approach for patients with proliferative chronic 
myelomonocytic leukaemia and mild-to-moderate leucocytosis; given the likelihood of 
leukaemoid reactions, cytokine release syndrome, and severe acute respiratory distress 
syndrome with COVID-19 in this group, the careful lowering of white blood cell count 
in cases of extreme leucocytosis in asymptomatic patients should be done with low 
doses of hydroxycarbamide while monitoring for the emergence of cytopenias
• Early initiation of cytokine modulators, such as anakinra and tocilizumab, could be 
considered for patients symptomatic for COVID-1946,47
• Erythropoiesis-stimulating agents or erythropoiesis maturation agents should be 
used in the management of anaemia to minimise transfusion burden
Supportive care
• Erythropoiesis-stimulating agents or erythropoiesis maturation agents should be 
used in the management of anaemia to minimise transfusion burden
• Transfusion contingency plans should be followed
• Use of granulocyte colony-stimulating factor should be carefully considered; we do 
not recommend routine use in patients with splenomegaly given the associated risk 
of splenic rupture
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We acknowledge that the recommendations provided 
in this Viewpoint might not be generalisable because of 
regional differences in health-care infrastructure and 
individual circumstances. That said, the guidance we 
have provided in this Viewpoint is adapted from available 
literature supporting guidelines for oncological manage-
ment that minimise patient–provider inter actions and 
inpatient hospital stays.
Disease-specific advisory groups have started to issue 
guidance on how to best provide care in the face of a 
rapidly accelerating outbreak, but these recom mendations 
are based largely on expert consensus. Robust data 
substantiating these recommendations are currently 
scarce. Reporting of patient outcomes and epidemiological 
data in the context of COVID-19 is urgently needed to 
support the evidence-based management of patients with 
haematological malignancies in the future. Now, more 
than ever, patients with leukaemia need the support of the 
oncological community to help balance the risks and 
benefits and allow for the best possible outcomes in these 
extraordinary circumstances.
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